BRPI0317064B8 - composições compreendendo células dendríticas parcialmente amadurecidas in vitro - Google Patents

composições compreendendo células dendríticas parcialmente amadurecidas in vitro

Info

Publication number
BRPI0317064B8
BRPI0317064B8 BRPI0317064A BR0317064A BRPI0317064B8 BR PI0317064 B8 BRPI0317064 B8 BR PI0317064B8 BR PI0317064 A BRPI0317064 A BR PI0317064A BR 0317064 A BR0317064 A BR 0317064A BR PI0317064 B8 BRPI0317064 B8 BR PI0317064B8
Authority
BR
Brazil
Prior art keywords
dendritic cells
partially matured
vitro
tumor
matured
Prior art date
Application number
BRPI0317064A
Other languages
English (en)
Other versions
BR0317064A (pt
BRPI0317064B1 (pt
Inventor
L Bosch Marnix
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Publication of BR0317064A publication Critical patent/BR0317064A/pt
Publication of BRPI0317064B1 publication Critical patent/BRPI0317064B1/pt
Publication of BRPI0317064B8 publication Critical patent/BRPI0317064B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"administração de células dendríticas parcialmente amadurecidas in vitro para o tratamento de tumores". a presente invenção refere-se a populações de células compreendendo células dendríticas parcialmente amadurecidas que podem ser usadas para a administração a indivíduos tendo um tumor. as células dendríticas parcialmente amadurecidas, que estiveram em contato com um agente de amadurecimento de células dendríticas durante cerca de 1 a cerca de 10 horas, ou mais, absorvem e processam antígenos de tumor eficazmente na área do sítio do tumor, completam o amadurecimento e podem, subseqüentemente, migrar para os linfonodos de um indivíduo tratado. uma vez no linfonodo, as células dendríticas apresentando antígenos agora completamente amadurecidas secretam as citocinas apropriadas (por exemplo tnf (alfa) e il-2) e contatam as células t induzindo uma resposta imune antitumor substancial.
BRPI0317064A 2002-12-06 2003-12-05 composições compreendendo células dendríticas parcialmente amadurecidas in vitro BRPI0317064B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43126702P 2002-12-06 2002-12-06
US60/431,267 2002-12-06
PCT/US2003/038672 WO2004053072A2 (en) 2002-12-06 2003-12-05 Administration of dendritic cells partially matured in vitro for the treatment of tumors

Publications (3)

Publication Number Publication Date
BR0317064A BR0317064A (pt) 2005-10-25
BRPI0317064B1 BRPI0317064B1 (pt) 2020-11-03
BRPI0317064B8 true BRPI0317064B8 (pt) 2021-05-25

Family

ID=32507696

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0317064A BRPI0317064B8 (pt) 2002-12-06 2003-12-05 composições compreendendo células dendríticas parcialmente amadurecidas in vitro

Country Status (19)

Country Link
US (2) US20060057120A1 (pt)
EP (2) EP1567155B1 (pt)
JP (2) JP4859169B2 (pt)
KR (1) KR101144196B1 (pt)
CN (2) CN102600461B (pt)
AT (1) ATE486125T1 (pt)
AU (2) AU2003293411B2 (pt)
BR (1) BRPI0317064B8 (pt)
CA (1) CA2509058A1 (pt)
DE (1) DE60334725D1 (pt)
DK (1) DK1567155T3 (pt)
ES (1) ES2354944T3 (pt)
HK (1) HK1082180A1 (pt)
IL (1) IL169002A (pt)
MX (1) MXPA05006042A (pt)
PL (1) PL377209A1 (pt)
PT (1) PT1567155E (pt)
RU (1) RU2348418C2 (pt)
WO (1) WO2004053072A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1567155E (pt) * 2002-12-06 2011-01-28 Northwest Biotherapeutics Inc Administração de células dendríticas parcialmente amadurecidas in vitro para o tratamento de tumores
US20070134273A1 (en) * 2004-02-10 2007-06-14 Francois Romagne Composition and method for the treatment of carcinoma
US20060216269A1 (en) * 2004-09-17 2006-09-28 Kenichiro Hasumi Dendritic cell tumor injection (DCTI) therapy
US8076132B2 (en) * 2004-09-17 2011-12-13 Hasumi International Research Foundation Dendritic cell tumor injection (DCTI) therapy
WO2006095330A2 (en) * 2005-03-10 2006-09-14 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases
WO2007001200A1 (fr) * 2005-06-23 2007-01-04 Obschestvo S Ogranichennoi Otvetsvennostyu 'rusgen' Cellules dendritiques matures chargees d'un polylysat de tumeurs, et vaccin antitumoral a base desdites cellules
AR060424A1 (es) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
WO2008133595A1 (en) * 2007-04-26 2008-11-06 Newbiomed Pika Pte Ltd Compositions and methods for stimulating an immune response in-vivo and in-vitro
WO2008151389A1 (en) * 2007-06-15 2008-12-18 Macfarlane Burnet Institute For Medical Research And Public Health Limited Chemically modified macromolecules
EP2072617A1 (en) * 2007-12-12 2009-06-24 Trimed Biotech GmbH Method for producing dendritic cells
EP3293255A1 (en) * 2008-03-27 2018-03-14 Asterias Biotherapeutics, Inc. Differentiation of primate pluripotent stem cells to hematopoietic lineage cells
US8679834B2 (en) * 2009-07-09 2014-03-25 TiGenix S.A.U Methods and compositions for use in cellular therapies
EP2534242B1 (en) * 2010-02-10 2016-04-20 Immunicum AB Improved composition for inhibiting tumor cell proliferation
RU2530523C2 (ru) * 2012-03-29 2014-10-10 Олег Борисович Егоров Способ противоопухолевой иммунотерапии
SG11201510552WA (en) 2012-06-27 2016-01-28 Hasumi Internat Res Foundation Therapy and method for intratumorally introducing cytotoxic t lymphocyte and/or nkt cell with anti-tnf and/or anti-il-10
GB201300049D0 (en) * 2013-01-03 2013-02-20 Transimmune Ag Method for obtaining immuno-stimulatory dendritic cells
EP3065772A4 (en) 2013-11-05 2017-09-13 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
GB201413665D0 (en) * 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
CN107849537A (zh) * 2015-06-30 2018-03-27 西北生物治疗药物公司 诱发改善的或增加的抗肿瘤免疫应答的经最佳活化的树突细胞
DK3350318T3 (da) * 2015-09-15 2022-07-11 Northwest Biotherapeutics Inc Fremgangsmåder relateret til aktiverede dendritiske cellesammensætninger til individer med fremskredne cancersygdomme
KR101749165B1 (ko) * 2016-06-07 2017-06-23 충남대학교산학협력단 Rv2299c 또는 Rv2299c와 ESAT-6 융합한 단백질을 포함하는 수지상 세포의 성숙화 촉진용 조성물
WO2018160666A1 (en) * 2017-02-28 2018-09-07 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Short-term activated dc1s and methods for their production and use
GB201711379D0 (en) * 2017-07-14 2017-08-30 Univ Cape Town Maturation of dendritic cells
CN109957548B (zh) * 2017-12-26 2022-03-18 上海尚泰生物技术有限公司 一种基因修饰的树突状细胞疫苗
GB2624871A (en) * 2022-11-29 2024-06-05 Alv B As Process for preparing a population of dendritic cells and immunotherapy using the same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333433T2 (de) 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US6797488B1 (en) * 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
CN1330557A (zh) * 1998-09-15 2002-01-09 匹兹堡大学联邦系统高等教育 原位注射具有基因上增进细胞因子表达的抗原呈递细胞
CN1321189A (zh) * 1998-10-02 2001-11-07 三菱化学株式会社 细胞性免疫的诱导方法以及被诱导了细胞免疫的细胞
US6649158B1 (en) * 1998-10-15 2003-11-18 Canji, Inc. Methods and compositions to induce antitumor response
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
WO2000061132A1 (en) * 1999-04-14 2000-10-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft
US20030108527A1 (en) * 1999-12-28 2003-06-12 Tsukasa Seya Maturation-promoting agent for immature dendrtic cells
JP2002069001A (ja) * 2000-08-29 2002-03-08 Asahi Kasei Corp 樹状細胞を主成分とする細胞ワクチン
US20020094545A1 (en) 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
AU2002326463A1 (en) * 2001-07-25 2003-02-17 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
WO2003022215A2 (en) * 2001-09-06 2003-03-20 Northwest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
PT1567155E (pt) * 2002-12-06 2011-01-28 Northwest Biotherapeutics Inc Administração de células dendríticas parcialmente amadurecidas in vitro para o tratamento de tumores
MXPA05009178A (es) * 2003-02-27 2006-03-08 Northwest Biotherapeutics Inc Generacion de celulas dendriticas a partir de celulas precursoras dendriticas monociticas con gm-csf en ausencia de citocinas adicionales.

Also Published As

Publication number Publication date
ATE486125T1 (de) 2010-11-15
JP2006510667A (ja) 2006-03-30
RU2005121256A (ru) 2006-02-10
WO2004053072A3 (en) 2005-06-16
JP4859169B2 (ja) 2012-01-25
EP2260861A1 (en) 2010-12-15
CN102600461A (zh) 2012-07-25
IL169002A (en) 2015-01-29
US20060057120A1 (en) 2006-03-16
JP5707284B2 (ja) 2015-04-30
AU2003293411A1 (en) 2004-06-30
EP1567155B1 (en) 2010-10-27
RU2348418C2 (ru) 2009-03-10
ES2354944T3 (es) 2011-03-21
PL377209A1 (pl) 2006-01-23
KR101144196B1 (ko) 2012-05-21
MXPA05006042A (es) 2005-09-21
DE60334725D1 (de) 2010-12-09
BR0317064A (pt) 2005-10-25
BRPI0317064B1 (pt) 2020-11-03
CN102600461B (zh) 2017-07-14
HK1082180A1 (en) 2006-06-02
CN1738619B (zh) 2012-04-18
EP1567155A4 (en) 2006-12-13
US20120251561A1 (en) 2012-10-04
WO2004053072A2 (en) 2004-06-24
CA2509058A1 (en) 2004-06-24
KR20050084189A (ko) 2005-08-26
AU2003293411B2 (en) 2010-10-28
JP2011246493A (ja) 2011-12-08
EP1567155A2 (en) 2005-08-31
AU2011200352A1 (en) 2011-02-17
DK1567155T3 (da) 2011-02-14
CN1738619A (zh) 2006-02-22
PT1567155E (pt) 2011-01-28
AU2011200352B2 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
BRPI0317064B8 (pt) composições compreendendo células dendríticas parcialmente amadurecidas in vitro
ATE153856T1 (de) Zusammensetzung zur stimulierung des immunsystems
CY1122817T1 (el) Νεα αντι-il 13 αντισωματα και χρησεις αυτων
BR112021016728A2 (pt) Bactérias imunostimulatórias projetadas para colonizar tumores, residentes em tumores células imunológicas e o microambiente tumoral
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
NO821832L (no) Fremgangsmaate for fremstilling av allergenholdige kapsler
DK0708772T3 (da) Imidazo[4,5,-c]pyridin-4-aminer
BR9714349A (pt) L-nucleosìdeos purina, seus análogos e utilizacões dos mesmos
BR9910251A (pt) Estimulação hematopoiética
BRPI0515316A (pt) compostos de imidazoquinolina
AR031250A1 (es) Composiciones y metodos para la terapia y el diagnostico del cancer de pulmon
DE60233576D1 (de) Interleukin-2 und Gamma Delta T Zellaktivator enthaltende Zusammensetzungen und deren Verwendungen
HUP9900681A2 (hu) TH1/TH2-citokinexpresszió modulálása Ribavirinnel és Ribavirin-analógokkal, aktivált T-limfocitákban
CY1116164T1 (el) Προδρομη 4-σουλφαταση ν-ακετυλογαλακτο σαμινης, μεθοδοι θεραπευτικης αγωγης που χρησιμοποιουν το εν λογω ενζυμο και μεθοδοι για παραγωγη και καθαρισμο του εν λογω ενζυμου
DE3688038D1 (de) Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst.
Habibi et al. Cytokine gene expression in healing and non‐healing cases of cutaneous leishmaniasis in response to in vitro stimulation with recombinant gp63 using semi‐quantitative RT–PCR
SE8802569L (sv) Foerbaettringar vid eller avseende somatosstatiner
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
ATE244570T1 (de) Immunmodulierende zusammensetzungen aus galle
ATE174798T1 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
BR9910187A (pt) Processo e composição para induzir uma resposta anti-tumor em um paciente mamìfero sofrendo de um tumor
AR034920A1 (es) Metodos para el tratamiento de enfermedades intestinales inflamatorias
BRPI0410761A (pt) uso de leucina, e, composição para administração entérica a pacientes
BR0313048A (pt) Uso de alquilfosfocolinas em combinação com medicamentos antitumorais
ES2137172T3 (es) Vacunas antitumorales que comprenden celulas transfectadas con il-6.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: "PARA: INT. CL. A61K 31/44

Ipc: A61K 31/44 (2011.01), C12N 5/00 (2011.01), C12N 5/

Free format text: PARA: INT. CL. A61K 31/44; C12N 5/00; C12N 5/02; A61P 35/00

Ipc: A61K 31/44 (2011.01), C12N 5/00 (2011.01), C12N 5/

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/12/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2751 DE 26-09-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.